Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis.
Br J Dermatol
; 177(6): 1562-1574, 2017 12.
Article
in En
| MEDLINE
| ID: mdl-28755394
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Psoriasis
/
Dermatologic Agents
/
Biosimilar Pharmaceuticals
/
Adalimumab
Type of study:
Clinical_trials
Limits:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Br J Dermatol
Year:
2017
Document type:
Article
Affiliation country:
Canada
Country of publication:
United kingdom